Please login to the form below

Not currently logged in

Silence Therapeutics adds to leadership team

Dr Dmitry Samarsky and Dr Andy Richards join

London-headquartered RNA therapeutics specialist Silence Therapeutics has appointed Dr Dmitry Samarsky as its new chief scientific officer, to take effect on 14 September.

Dr Samarsky joins the company from OliX Pharmaceuticals, where he served as senior vice president of technology and global business development.

Prior to this, he held the same title at RiboBio, an oligonucleotide-focused biotech based in China, between 2011 and 2015, and served as vice president of technology development at RXi Pharmaceuticals and director of technology development at Dharmacon.

Ali Mortazavi, chief executive officer of Silence Therapeutics, said: “We have undertaken an extensive search to find a CSO with experience in RNA therapeutics and are pleased to have recruited Dmitry, who brings a combination of deep technical expertise and commercial knowledge to Silence.

“Dmitry will be key in leading our efforts as we increase our liver focus and research and development in conjugated siRNAs. I look forward to working closely with him.”

Meanwhile, Silence Therapeutics has also appointed Dr Andy Richards as non-executive director and a member of the board with immediate effect.

Dr Richards currently chairs several UK biotechs, including Abcodia, Babraham Bioscience Technologies, Congenica and IXICO.

He previously held positions at AstraZeneca and PA Technology, and has contributed to the founding of Vectura, Arakis and Chiroscience Group.

Dr Stephen Parker, chairman of Silence Therapeutics, said: “We are delighted to have attracted Andy Richards, a recognised leader in the UK biotechnology sector, to join the board of Silence.

“We look forward to the benefit of his considerable experience in the commercial aspects of the sector as well as his overall guidance.”

8th September 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....